STOCK TITAN
  1. Home
  2. News
  3. FGEN

FibroGen Inc - FGEN STOCK NEWS

Welcome to our dedicated news page for FibroGen (Ticker: FGEN), a resource for investors and traders seeking the latest updates and insights on FibroGen.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect FibroGen's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of FibroGen's position in the market.

News
FibroGen Announces Clinical Data from Dose Escalation Phase 1b Study of FG-3246 (FOR46) in Combination with Enzalutamide in Patients with Metastatic Castration Resistant Prostate Cancer will be Presented at the 2024 American Society of Clinical Oncology Annual Meeting
Rhea-AI Summary
FibroGen, Inc. announces the selection of clinical data from the dose escalation portion of the Phase 1b/2 study of FG-3246 in combination with enzalutamide for a poster presentation at the 2024 American Society of Clinical Oncology Annual Meeting. The presentation focuses on a novel antibody-drug conjugate targeting a tumor-specific epitope of CD46 in patients with metastatic castration resistant prostate cancer.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
clinical trial
-
News
FibroGen Announces Topline Results from Phase 1 Monotherapy Study of FG-3246 in Patients with Metastatic Castration-Resistant Prostate Cancer
Rhea-AI Summary
FibroGen, Inc. (NASDAQ: FGEN) announces positive topline data from the Phase 1 study of FG-3246, an anti-CD46 antibody drug conjugate, in metastatic castration-resistant prostate cancer patients. Key findings include a median radiographic progression free survival of 8.7 months, PSA50 response in 36% of patients, and a radiographic objective response rate of 20%. The company plans to initiate Phase 2 trials in the second half of 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-31.94%
Tags
clinical trial
-
News
FibroGen to Present at 23rd Annual Needham Virtual Healthcare Conference
Rhea-AI Summary
FibroGen, Inc. (FGEN) CEO to present at Needham Healthcare Conference, offering virtual one-on-one meetings with investors. Event details, webcast link, and replay information provided.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.58%
Tags
conferences
News
FibroGen Appoints Deyaa Adib, M.D. as Chief Medical Officer
Rhea-AI Summary
FibroGen, Inc. appoints Dr. Deyaa Adib, an experienced oncology leader, as Senior Vice President & Chief Medical Officer. His extensive background in oncology drug development will drive the company's oncology pipeline forward, focusing on bringing novel cancer therapies to patients in need.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5%
Tags
management
-
News
FibroGen Reports Fourth Quarter and Full Year 2023 Financial Results
Rhea-AI Summary
FibroGen, Inc. (FGEN) reports positive financial results for FY 2023, with a 5% increase in total net revenue. The company anticipates topline data from pivotal pancreatic cancer trials in 2Q 2024 and additional data from a Phase 1 study in 1Q 2024. FibroGen also regains rights to roxadustat from AstraZeneca in certain territories, showing robust volume growth in China. The company's cost reduction plan has been successful, with a cash runway into 2026.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
14.59%
Tags
earnings
-
News
FibroGen Regains All Rights to Roxadustat from AstraZeneca in the United States and Other AstraZeneca Territories, Except China and South Korea
Rhea-AI Summary
FibroGen terminates U.S./RoW roxadustat collaboration agreement with AstraZeneca, retains rights outside China. FibroGen to explore licensing opportunities for roxadustat. Roxadustat remains a leader in China for CKD anemia treatment.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
14.59%
Tags
none
News
FibroGen to Report Fourth Quarter and Full Year 2023 Financial Results
Rhea-AI Summary
FibroGen, Inc. (FGEN) to announce Q4 and full year 2023 financial results on February 26, 2024. Conference call scheduled to discuss corporate and financial performance.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-17.81%
Tags
conferences earnings
-
News
FibroGen To Host Part I of Virtual KOL Investor Event Series to Review Pamrevlumab Clinical Program in Pancreatic Cancer on February 13, 2024
Rhea-AI Summary
FibroGen, Inc. (NASDAQ: FGEN) will host a virtual KOL investor event featuring discussions on the clinical development program for pamrevlumab and FG-3246, potential first-in-class monoclonal antibodies targeting CTGF for pancreatic cancer treatment and CD46 targeting ADC for mCRPC, respectively. The event will provide information on the mechanism of action, pre-clinical and Phase 1/2 data, and ongoing trials for both treatments.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.87%
Tags
conferences
-
News
FibroGen Announces Completion of the Pamrevlumab Arm in Precision Promise, Pancreatic Cancer Action Network’s Phase 2/3 Adaptive Platform Trial for Metastatic Pancreatic Cancer
Rhea-AI Summary
FibroGen, Inc. (NASDAQ: FGEN) announced the completion of the pamrevlumab experimental arm in the Pancreatic Cancer Action Network's Precision PromiseSM Phase 2/3 adaptive platform trial. The topline data from this registration study is anticipated in the second quarter of 2024. Pamrevlumab achieved a protocol pre-specified ≥ 35% predictive probability of success for the primary endpoint of overall survival at the completion of the trial and graduated to the second and final stage of the trial in the third quarter of 2022. This marks a significant milestone in potential new therapy for patients with metastatic pancreatic cancer.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
13.4%
Tags
clinical trial
News
FibroGen Presents Data from Phase 3 MATTERHORN Trial of Roxadustat in Patients with Anemia of Lower Risk Transfusion-Dependent Myelodysplastic Syndromes at American Society of Hematology Annual Meeting
Rhea-AI Summary
FibroGen, Inc. (FGEN) presented efficacy and safety data from the MATTERHORN Phase 3 clinical study of roxadustat for the treatment of anemia in patients with lower risk transfusion-dependent myelodysplastic syndromes (MDS) at the 65th American Society of Hematology (ASH) Annual Meeting and Exposition. The results showed a larger percentage of patients achieved transfusion independence with roxadustat vs. placebo in patients with higher transfusion burden. Roxadustat, an oral hypoxia-inducible factor prolyl hydroxylase inhibitor, demonstrated potential as an important new therapy for this patient population. The presentation was selected for the '2024 Highlights of ASH'.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
clinical trial
Stock FGEN logo
FibroGen Inc

Nasdaq:FGEN

FGEN Rankings

#4290 Ranked by Market Cap
#5525 Ranked by Stock Gains
N/A Ranked by Dividends

FGEN Stock Data

128.40M
82.99M
6.37%
71.45%
5.26%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
US
San Francisco

About FGEN

fibrogen is a research-based biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutics to treat serious unmet medical needs. the company has built upon its extensive research experience in fibrosis and hypoxia-inducible factor (hif) biology to generate clinical programs targeting multiple therapeutic areas. fibrogen's most advanced product candidate, roxadustat (fg-4592), is an oral small molecule inhibitor of hif prolyl hydroxylases (hif-phs), in phase 3 clinical development for the treatment of anemia in chronic kidney disease (ckd). our second product candidate, fg-3019, is a monoclonal antibody in phase 2 clinical development for the treatment of idiopathic pulmonary fibrosis (ipf), pancreatic cancer and liver fibrosis. for more information please visit: www.fibrogen.com.